Mirapexin (Pramipexole Dihydrochloride Monohydrate)

Pramipexole, the active ingredient in Mirapexin, is a dopamine agonist presented as an oral tablet for oral use. It is employed to manage symptoms of Parkinson's disease and restless legs syndrome in adult patients by stimulating dopamine receptors in the central nervous system, thereby improving motor control and reducing uncomfortable sensations.

GNH USA supplies Mirapexin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for importers.

Mirapexin (pramipexole) is a dopamine agonist used in the management of movement disorders. - Parkinson's disease (early stage): Helps control motor symptoms and may delay the need for levodopa. - Parkinson's disease (advanced stage): Provides adjunctive therapy to reduce motor fluctuations. - Restless legs syndrome: Decreases leg discomfort and the urge to move, improving sleep quality.

Pramipexole may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: feeling light‑headed or unsteady. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate head pain. - Orthostatic hypotension: drop in blood pressure upon standing. - Peripheral edema: swelling of the lower limbs.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances. - Impulse control disorders: compulsive gambling, shopping, or eating. - Sudden onset of sleep: episodes of unexpected sleep. - Neuroleptic malignant-like syndrome: rare severe reaction with fever and rigidity. - Severe depression or suicidal thoughts: worsening mood or suicidal ideation. - Allergic reactions: rash, swelling, or anaphylaxis.

When prescribing Mirapexin, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose in patients with reduced kidney function. - Cardiovascular disease: monitor for orthostatic hypotension and arrhythmias. - Psychiatric history: watch for hallucinations, depression, or impulse control changes. - Elderly patients: start at low dose and titrate slowly due to increased sensitivity. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Pramipexole can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Antipsychotics (e.g., haloperidol, risperidone): may antagonize dopamine agonist effect. - MAO‑B inhibitors (e.g., selegiline): increase risk of hypertensive reactions.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., alcohol, benzodiazepines): may enhance somnolence. - Antihypertensive agents: additive effect on blood pressure, monitor for hypotension. - Serotonergic drugs (e.g., SSRIs): potential for serotonin syndrome, observe symptoms. - Dopamine antagonists (e.g., metoclopramide): may reduce therapeutic benefit.